Opinion|Videos|March 3, 2025

New Systemic Therapies for Pediatric Atopic Dermatitis: Dupilumab and IL-13 Inhibitors

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Video content above is prompted by the following:

Moving on to systemic treatment options, let’s discuss some of the newer systemic treatment options available for pediatric AD, including mechanism of action, efficacy, and safety:

  • Tralokinumab

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME